April 29, 2017
Recommended Topic Related To:

Ingrezza

"Preliminary results from a study of spironolactone in Duchenne muscular dystrophy (DMD) suggest that the drug is safe in this patient group and may preserve left ventricular function.

Presenting data from the study at the recent Ameri"...

A A A

Ingrezza

INGREZZA™
(valbenazine) Capsules

DRUG DESCRIPTION

INGREZZA contains valbenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor, present as valbenazine tosylate salt, with the chemical name, L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10- dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester, 4-methylbenzenesulfonate (1:2). Valbenazine tosylate is slightly soluble in water. Its molecular formula is C38H54N2O10S2, and its molecular weight is 762.97 g/mol (ditosylate salt) with the following structure:

INGREZZATM™ (valbenazine) Structural Formula Illustration

The molecular formula of valbenazine free base is C24H38N2O4 and its molecular weight is 418.57.

INGREZZA capsules are intended for oral administration only. Each capsule contains 73 mg of valbenazine tosylate, which is equivalent to 40 mg of valbenazine free base. It also contains the following inactive ingredients: mannitol, partially pregelatinized starch, fumed silica, and magnesium stearate. The capsule shell contains gelatin, candurin silver fine, FD&C Red#40, and FD&C Blue#1.

Last reviewed on RxList: 4/17/2017
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.